By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Deciphera Pharmaceuticals 

1505 Wakarusa Drive

Lawrence  Kansas  66047  U.S.A.
Phone: 785-838-3767 Fax: 785-838-3747



Company News
Massachusetts' Deciphera Seeks $100 Million IPO 9/19/2017 6:24:58 AM
Deciphera Reports Updated Data From Ongoing Phase I Clinical Study Of DCC-2618 At The European Society Of Medical Oncology 2017 Congress 9/11/2017 6:42:16 AM
Deciphera Announces FDA Orphan Drug Designation For DCC-2618 For The Treatment Of Glioblastoma Multiforme And Anaplastic Astrocytoma 9/5/2017 8:32:17 AM
Deciphera Reports Updated Phase I Clinical Study Results With DCC-2618 At 2017 ASCO Annual Meeting 6/5/2017 6:42:49 AM
Massachusetts' Deciphera Banks $52 Million to Advance Oncology Pipeline 6/1/2017 6:31:18 AM
Deciphera To Report Phase I Clinical Study Results With DCC-2618 At The 2017 ASCO Annual Meeting 5/18/2017 6:48:07 AM
Deciphera Release: Translational Research Results Confirm The Broad Activity Of DCC-2618 In GIST Patients With Difficult To Treat Drug Resistant KIT Mutations 4/3/2017 10:30:25 AM
Deciphera Initiates A Phase 1 Clinical Trial Of DCC-3014 In Patients With Advanced Malignancies 3/6/2017 6:16:18 AM
Deciphera Reports Encouraging Clinical Results With DCC-2618 In Genetically-Defined Cancers With Drug Resistant Mutations 12/1/2016 8:18:26 AM
Deciphera Appoints Christopher J. Morl, M.B.A. As Chief Business Officer 10/6/2016 10:17:43 AM